Drug profile · INN
human normal immunoglobulin (scig)
HIZENTRA
human normal immunoglobulin (scig) (HIZENTRA) is a replacement therapy, immunomodulatory effects.
EMA: approved Antiinfectives for systemic use (J06) J06BA01
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — human normal immunoglobulin (scig)
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
human normal immunoglobulin (scig) (HIZENTRA) is a replacement therapy, immunomodulatory effects.
Key facts
INN human normal immunoglobulin (scig)
Brand HIZENTRA
Mechanism Replacement therapy, immunomodulatory effects
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BA01
Mechanism of action
Replacement therapy, immunomodulatory effects
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is human normal immunoglobulin (scig)?
human normal immunoglobulin (scig) (HIZENTRA) is a replacement therapy, immunomodulatory effects.
What is the brand name for human normal immunoglobulin (scig)?
HIZENTRA is a marketed brand name for human normal immunoglobulin (scig). Check FDA Drugs@FDA for the current US label holder and prescribing information.